# Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Study · id `cardio:ct-nct04988386` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04988386](<https://clinicaltrials.gov/study/NCT04988386>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04988386

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 389 participants.

## Technical summary

Registry record NCT04988386. Allocation not applicable; no masking; primary purpose treatment. Start 2021-10-27 (actual); primary completion 2028-04-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 389 participants (enrolled count; ClinicalTrials.gov record NCT04988386, source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)
- Started: 2021-10-27 (actual) (ClinicalTrials.gov record NCT04988386, source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)
- Primary completion: 2028-04-15 (anticipated) (ClinicalTrials.gov record NCT04988386, source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)
- Completion: 2028-05-15 (anticipated) (ClinicalTrials.gov record NCT04988386, source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Brazil; Canada; Czechia; Denmark; Greece; Ireland; Israel; Italy; Netherlands; New Zealand; Portugal; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT04988386, source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04988386-2025-10-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
- Acronym: AG10
- Condition: Amyloid Cardiomyopathy, Transthyretin-Related
- Intervention (Drug): Acoramidis (AG10)
- Lead sponsor: Eidos Therapeutics, a BridgeBio company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry lists this organization as the lead sponsor: Eidos Therapeutics, a BridgeBio company (`cardio:org-eidos-therapeutics-a-bridgebio-company`)

## Provenance

Content hash: 2cd447227c63ac94b2828a5fe9eb27d3fa9f481987c861c753ca07200967f9e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
